BTB Korea Co Ltd

BTB Korea Co Ltd has a debt-to-equity ratio of 0.54 and a current ratio of 2.61, indicating moderate leverage and strong short-term liquidity. However, the company reported negative operating and net income, with operating cash flow of -5.97 billion KRW and free cash flow of -3.66 billion KRW, signaling cash flow constraints. Profitability metrics are weak, with a return on equity of -16.18% and return on assets of -8.89%, both significantly below the industry median for Biotechnology & Medical Research firms. The company's gross margin of 21.12% (6.77 billion KRW gross profit on 32.03 billion KRW revenue) is also below the sector average, reflecting pricing pressures or cost inefficiencies. The company operates through two segments: Bio Business and Medical Device Business. Revenue concentration data is not disclosed, but the Bio Business segment focuses on biotechnology research reagents and kits, while the Medical Device Business focuses on anti-aging beauty devices. No geographic breakdown is provided, but the company is Korea-based and likely serves regional markets. Outlook for the current fiscal year is negative, with continued operating losses and declining cash balances. No specific revenue growth rate is provided, but the company's negative operating cash flow and free cash flow suggest a challenging operating environment. Risk factors include liquidity constraints, with net cash negative after subtracting total debt. The company has low dilution potential, with no recent share issuance or ATM/shelf disclosures reported. No significant regulatory or geopolitical risks are highlighted in the industry configuration, but the healthcare sector is subject to policy changes and reimbursement pressures. Recent events include a name change from GTG Wellness Co Ltd to BTB Korea Co Ltd, and a 10-K filing disclosing ongoing losses and liquidity challenges. No recent earnings call transcripts or major regulatory filings are available in the input data.